Sanofi India is currently trading at Rs. 8175.10, up by 215.20 points or 2.70% from its previous closing of Rs. 7959.90 on the BSE.
The scrip opened at Rs. 7985.00 and has touched a high and low of Rs. 8240.90 and Rs. 7959.00 respectively. So far 2533 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 8999.00 on 24-Aug-2020 and a 52 week low of Rs. 7427.75 on 27-Apr-2021.
Last one week high and low of the scrip stood at Rs. 8240.90 and Rs. 7842.00 respectively. The current market cap of the company is Rs. 18561.53 crore.
The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.28% and 11.33% respectively.
Sanofi India’s board has approved a transaction for the slump sale and transfer of the company’s Nutraceuticals business, on a going concern basis to Universal Nutriscience for a consideration of Rs 5,870 million including debt like obligations (such as retirals and provision for sales returns), subject to customary working capital adjustments and post-closing adjustment in connection with certain contractual arrangements between the parties. Completion of the transaction is anticipated within the next 3 months, subject to fulfillment of conditions as set out in the Business Transfer Agreement.
The Nutraceuticals business of the company comprises 16 brands and 30 SKUs. These along with related business assets and liabilities including contracts, intellectual property rights, inventory, and all employees associated with this business will transition to Universal Nutriscience. This decision will help the Company to invest and focus on its strategic growth pillars, while allowing the Nutraceuticals business and the people associated with it, to significantly benefit in a company specialized in Nutraceuticals and Wellness. The Board of Directors of the company at its meeting held on July 27, 2021 has approved the same.
Sanofi India is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
